2023
Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018)
Shahrir S, Crothers K, McGinnis K, Chan K, Baeten J, Wilson S, Butt A, Pisani M, Baldassarri S, Justice A, Williams E. Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018). Open Forum Infectious Diseases 2023, 10: ofad089. PMID: 36968969, PMCID: PMC10034589, DOI: 10.1093/ofid/ofad089.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyAging Cohort StudyHuman immunodeficiency virusCessation medicationsCohort studyCurrent smokersCurrent smokingHIV statusImmunodeficiency virusRelative riskHuman immunodeficiency virus statusSmoking cessation medicationsNicotine replacement therapyRates of receiptDangers of smokingOutpatient prescriptionsReplacement therapyPharmacy dataVirus statusTobacco useAnnual rateMedicationsSmokingPWHStatistical difference
2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh riskReceipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV
Shahrir S, Crothers K, McGinnis KA, Chan KCG, Baeten JM, Wilson SM, Butt AA, Pisani MA, Baldassarri SR, Justice A, Williams EC. Receipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV. Progress In Cardiovascular Diseases 2020, 63: 118-124. PMID: 31987807, PMCID: PMC7251937, DOI: 10.1016/j.pcad.2020.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-HIV AgentsCardiovascular DiseasesFemaleHealth StatusHIV InfectionsHIV Long-Term SurvivorsHumansLongitudinal StudiesMaleMiddle AgedPreventive Health ServicesProspective StudiesProtective FactorsRisk AssessmentRisk FactorsRisk Reduction BehaviorSmokersSmokingSmoking CessationSmoking Cessation AgentsTime FactorsTreatment OutcomeUnited StatesVeterans HealthViral LoadConceptsNicotine replacement therapyVeterans Aging Cohort StudyMultivariable log-linear regression modelsPotential treatment disparitiesSmoking cessation pharmacotherapyPatient-level factorsAging Cohort StudyMental health disordersRates of receiptUninfected participantsUninfected patientsCardiovascular riskCessation pharmacotherapyCohort studyCurrent smokingHIV statusMultivariable analysisTreatment disparitiesReplacement therapyRelative riskHealth disordersPharmacotherapyPLWHSmokingHIV
2019
Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States
Rentsch CT, Tate JP, Steel T, Butt AA, Gibert CL, Huang L, Pisani M, Soo Hoo GW, Crystal S, Rodriguez-Barradas MC, Brown ST, Freiberg MS, Graber CJ, Kim JW, Rimland D, Justice AC, Fiellin DA, Crothers KA, Akgün KM. Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 80: 145-151. PMID: 30422912, PMCID: PMC6701630, DOI: 10.1097/qai.0000000000001904.Peer-Reviewed Original ResearchConceptsHepatitis C virusAlcohol-related diagnosesAdmission ratesMICU admissionAdmission riskC virusRelative riskIntensive care unit admission rateMedical intensive care unit admissionAge-adjusted admission ratesHCV mono-infected patientsIntensive care unit admissionVeterans Aging Cohort StudyHCV care providersCare unit admissionAging Cohort StudyAdjusted rate ratiosConfidence intervalsVeterans Health AdministrationUnhealthy alcohol useHIV monoHIV-/HCVUnit admissionCause hospitalizationHCV infection
2018
Gender and alcohol use
Matson TE, McGinnis KA, Rubinsky AD, Frost MC, Czarnogorski M, Bryant KJ, Edelman EJ, Satre DD, Catz SL, Bensley KM, Fiellin DA, Justice AC, Williams EC. Gender and alcohol use. AIDS 2018, 32: 2247-2253. PMID: 30005010, PMCID: PMC6136970, DOI: 10.1097/qad.0000000000001946.Peer-Reviewed Original ResearchConceptsAlcohol useHIV careViral suppressionART treatmentVeterans Aging Cohort Study (VACS) dataVeterans Health Administration patientsAUDIT-C alcoholHIV medical careHIV care continuumLarge national cohortCohort study dataPoisson regression modelsPrescribed ARTPrevalence of engagementRetrospective cohortNational cohortUS veteransWorse outcomesCare continuumRelative riskStratified analysisMedical careHIVGender modifiesWomen
2015
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA, Collaboration H. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The Lancet HIV 2015, 2: e335-e343. PMID: 26423376, PMCID: PMC4643831, DOI: 10.1016/s2352-3018(15)00108-3.Peer-Reviewed Original ResearchConceptsNeed of ARTHIV RNA viral loadCD4 countAntiretroviral therapyHIV-positive individualsMean survival timeImmediate initiationHIV diagnosisCohort studyViral loadRelative riskHigh-income countriesProportion of individualsSurvival timeInitiation of ARTART initiation strategiesImmediate antiretroviral therapyLow CD4 countMedian CD4 countObservational cohort studyAIDS-free survivalHIV-1 infectionDiagnosis of HIVViral load measurementsHIV-CAUSAL CollaborationAlcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011
Rentsch C, Tate JP, Akgün KM, Crystal S, Wang KH, Ryan Greysen S, Wang EA, Bryant KJ, Fiellin DA, Justice AC, Rimland D. Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011. AIDS And Behavior 2015, 20: 555-564. PMID: 25711299, PMCID: PMC4550577, DOI: 10.1007/s10461-015-1025-y.Peer-Reviewed Original ResearchConceptsAlcohol-related diagnosesHospitalization ratesUnited States veteransUninfected patientsCause hospitalizationHIV infectionStates veteransUninfected individualsMultivariable Cox proportional hazards modelsCox proportional hazards modelOverall hospitalization rateProportional hazards modelCancer admissionsAntiretroviral therapyMultivariable adjustmentHIV serostatusComorbidity variablesHospitalization trendsRelative riskHigh riskHazards modelHIVHospitalizationDisease categoriesPatients
2010
Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value?
Braithwaite RS, Fiellin DA, Nucifora K, Bryant K, Roberts M, Kim N, Justice AC. Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value? Value In Health 2010, 13: 535-542. PMID: 20345544, PMCID: PMC3032536, DOI: 10.1111/j.1524-4733.2010.00714.x.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionNonadherent patientsAdherence interventionsRelative riskRisk factorsAntiretroviral therapy adherence interventionsEffect sizeNonadherence risk factorsBehavioral risk factorsHIV careAntiretroviral adherencePatientsNonadherenceSocietal perspectiveIncremental costIntervention costsSmall effect sizesLife expectancyInterventionRisk reductionPlausible effect sizes
2009
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal Of Medicine 2009, 360: 1815-1826. PMID: 19339714, PMCID: PMC2854555, DOI: 10.1056/nejmoa0807252.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyRisk of deathAsymptomatic patientsHuman immunodeficiency virus (HIV) infectionCubic millimeterEarly-therapy groupImmunodeficiency virus infectionPrevious antiretroviral therapyCohort of patientsClinical characteristicsHIV infectionRelative riskEarly initiationVirus infectionCD4PatientsMedical careTherapyDeathCalendar yearInfectionRiskCountSurvivalGroup